Yissum - Research Development Company of the Hebrew University posted this:Treatment of Genetic Diseases Caused by Nonsense MutationTreatment of Genetic Diseases Caused by Nonsense Mutation Project ID : 6-2018-4579
Yissum - Research Development Company of the Hebrew University posted this:Novel Indoline Derivatives with Antioxidant and Anti-Inflammatory ActivityNovel Indoline Derivatives with Antioxidant and Anti-Inflammatory Activity Project ID : 7-2015-3171
Yissum - Research Development Company of the Hebrew University posted this:Novel Transdermal Delivery System of CannabinoidsCannabinoids Transdermal, enhanced and modulated administration due to an innovative biphasic composition Project ID : 6-2016-4334
Yissum - Research Development Company of the Hebrew University posted this:Products for Preventing Penetration Into the SkinKeywords: cosmetics, sunscreens Project ID : 6-2006-191
Yissum - Research Development Company of the Hebrew University posted this:Treatment Of Hepatic Encephalopathy And Liver CirrhosisA method for the treatment of hepatic encephalopathy comprising administering to a subject in need of such treatment an effective amount of D9-tetrahydrocannabinol (THC) or Cannabidiol. keywords: hepatic, encephalopathy Originally: 12-2007-1885, 12-2007-1878 12-2006-577- 3 projects combined into one Project ID : 12-2006-577
Yissum - Research Development Company of the Hebrew University posted this:Novel Compounds for the treatment of obesityNovel Compounds for the treatment of obesity Project ID : 6-2008-1996
Yissum - Research Development Company of the Hebrew University posted this:Floating sustained release of antioxidantsFloating Sustained Release Delivery systems of Polyphenols Project ID : 6-2009-2215
Yissum - Research Development Company of the Hebrew University posted this:Novel Compounds for the Treatment and Prevention of Autismbeta- carotene as treatment for autism Project ID : 6-2014-3058
Yissum - Research Development Company of the Hebrew University posted this:New Formulations for Oral, Nasal, Transdermal and Rectal CannabinoidsCBD Project ID : 6-2017-4448
Yissum - Research Development Company of the Hebrew University posted this:Treating Skin Toxicities Caused by Biological Cancer Drugs Applying Topical Specific Inhibitors to the Anti-Cancer DrugsMany of the antineoplastic tyrosine kinase inhibitors are associated with prominent and sometimes dose-limiting dermatologic complications. Of severe clinical implication are the specific EGFR inhibitors. Most patients treated with these drugs suffer from severe impairment to their quality of life and require reduction or interruption in the anti-cancer drug protocols. Treatment strategies today for treating skin toxicities from EGFR inhibitors show limited benefit and most patients require dose reductions or interruptions to the anti-cancer treatment protocols. Our proposal focuses on the development of a novel approach using formulation for treating skin toxicities caused by anti-neoplastic EGFR inhibitors by applying topical compounds that specifically and locally block the anti-cancer drugs. Our preliminary results have shown that blocking EGFR inhibitors binding to EGFR prevents keratinocyte death. We have identified small compounds that block EGFR inhibitors binding to its receptor and have developed topical slow release system that can deliver the target compounds to the hair follicle which is a major target for skin rash caused by EGFR inhibitors. Our novel approach will improve the quality of life of patients suffering from skin toxicity and help maintain an optimal anti-neoplastic dose thereby allowing more patients to receive full dose anti-cancer therapy and improve response to therapy Project ID : 6-2017-4450
Yissum - Research Development Company of the Hebrew University posted this:Novel Autotaxin Inhibitor Drug (XIIPHONATE) for Cancer and/or AsthmaWe propose a novel compound for the treatment of asthma. We suggest to use this new compound named XIIPHONATE as new lipid-mimetic molecule that inhibits recombinant Autotaxin (ATX), as a potential local, long-term treatment for asthma. This approach is based on the fact that a novel bioactive lipid mediator, Lysophosphatidic acid (LPA), has a pivotal role in the pathogenesis of asthma. It was reported that LPA is synthesized from LPC through the enzymatic activity of ATX. Clinical data show that the levels of ATX protein, and LPA are significantly elevated the in airspaces of patients with asthma. Thus, XIIPHONATE, will inhibit LPA overproduction that leads to the pathologic state. It will therefore present a new therapeutic modality for asthma. Project ID : 6-2016-4268
CD Genomics posted this:DNA & Genomics Sequencing ServiceCD Genomics proprietary GenSeqTM Technology provides advanced multi-omics and bioinformatics service solutions for its global The Specialties of GenSeqTM customers who do research in laboratory. Equipped with the broadest industrial array of cutting-edge technologies and coupled with a group of experienced scientists and bioinformaticians, CD Genomics possesses significant contributions to genetic research.
Universitat de Lleida posted this:Method based on a nutritional intervention to fight coccidiosisWe seek industrial partners with expertise in the sector of crop production to adopt a new technology useful to deliver optimized feed solution to fight coccidiosis. The type of partner sought is mainly for the regulatory codevelopment and the commercialization of our solution under a technology license agreement. The technology developed relates to a novel genetically engineered variety of maize accumulating extraordinary levels of carotenoids (β-carotene, lycopene, zeaxanthin and lutein). Poultry raised on this corn were healthy and exhibited substantially higher levels of resistance to coccidiosis, less foot pad dermatitis, reduced number of ulcers and less excretion of pathogen oocysts in feces. Carotenoids accumulate in several tissues (skin, dermis, muscles and fat), conferring high nutritional value and greater consumer acceptance.
University of Huelva posted this:New plasmid and strategy for expression of exogenous proteins in eukaryotic microalgae by translational fusion with a selectable markerThis plasmid solves the problems of low efficiency and instability of transgenes in the genetic manipulation of microalgae, as well as offers a procedure for the expression of high amounts of the protein of interest and better transformation efficiency
University of Huelva posted this:New procedure for the genetic transformation of plant cells and kit for carrying out said methodThe strategy for transformation is extremely simple and does not involves subcloning the gene of interest in any vector. The kit is not based on specific promoters or regulatory DNA sequences, thus it can be applied to many different plant species, from unicellular microalgae to higher plant protoplasts. Since the strategy is not based on specific promoter or regulatory DNA sequences, only the marker and the gene of interest sequences are inserted in the microalgal genome, avoiding the introduction of undeserible DNA sequences in the transformant strain. This is very important given the concern that transfer of exogenous DNA through transgenesis causes in the public opinion